ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

telitacicept

Also written as “Telitacicept”, “RC18 160mg” and “RC18 240mg”.

Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, IGA · Myasthenia Gravis · Sjogren's Syndrome · Lymphoma, Follicular, led by 3 companies.

Drug pageTelitacicept: every studyAll 54 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 8, 201725 company-led studies, 8 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGenits history only194 open or runningphase 3since Jan 8, 2017Aug 24, 2016Dec 31, 2026phase 3 · NCT07249632
Vor Biopharma42 open or runningphase 3since Mar 23, 2022Mar 23, 2022Mar 2027phase 3 · NCT06456580
Innovent Biologicsits history only22 open or runningphase 2since Sep 13, 2026Sep 13, 2026Jan 31, 2027phase 1 · NCT07886476

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vor Biopharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2018Named telitaciceptINNProposed as its International Nonproprietary Name in WHO's List 120
  2. Mar 23, 2022First study: phase 3 study in Lupus Erythematosus, SystemicFirst studyNCT05306574 · 91 enrolled · United States, Argentina, Australia and more
  3. Jun 7, 20242 phase 3 studiesNCT06456580, NCT06456567
  4. Feb 4, 2026Phase 3 study in Sjogren's SyndromeNCT07404865 · 250 planned · United States, Georgia

Ahead

  1. Mar 2027Primary completion: phase 3 study in Myasthenia GravisNCT06456580
  2. Dec 2028Primary completion: phase 3 study in Sjogren's SyndromeNCT07404865

TargetBeta

TNFRSF13B →read by rule
“A fusion protein composed of the extracellular domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) ”NCIt, by rule

Other programs on TNFRSF13B

ProgramCompanyFurthest phaseStudies
povetaciceptruleVertex Pharmaceuticalsphase 39
SHR-2173Jiangsu HengRui Medicinephase 28

Studies

All 4 Vor Biopharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07404865Sjogren's Syndrome · United States, Georgia3RecruitingDec 2028250
NCT06456580Myasthenia Gravis · United States, Argentina, Australia and more3Active, not recruitingMar 2027191
NCT06456567Lupus Erythematosus, Systemic · United States3WithdrawnJan 2, 20250
NCT05306574Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3TerminatedJan 6, 202591

How it is read

Names in the registry

  • “Telitacicept”, 11 entries
  • “RC18 160mg”, 3 entries
  • “RC18 240mg”, 3 entries
  • “RC18 240 mg”, 2 entries
  • “RC18 160 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.